active as cefpirome; the MIC for 90%o of strains tested (MIC90) was 1.0 p,g/ml. Against methicillin-resistant S.
aureus, E1077 was less active (MIC90, 64 ,ug/ml). For Enterobacter cloacae and Pseudomonas aeruginosa, E1077 was fourfold more active than cefpirome, with MIC90s of 1.0 and 16 ,ug/ml, respectively. For Proteus vulgaris, the MIC90 of E1077 was 32 ,ug/ml, which was fourfold greater than that of cefpirome. Against other gram-negative strains tested, the in vitro activity of E1077 was comparable to that of cefpirome. The broad antibacterial spectrum of E1077 was reflected by its in vivo efficacy against experimental septicemia caused by gram-positive and gram-negative bacteria. Against S. aureus 90 and P. aeruginosa E7, E1077 had activity superior to those of the reference compounds; against most other bacterial strains, the efficacy of E1077 was similar to that of cefpirome. Levels of E1077 in plasma and tissue of mice were studied. At 15 min after a single subcutaneous administration, E1077 displayed high peak levels (mean, 31.8 ± 3.1 ,ug/ml). These results indicate that the in vitro and in vivo efficacies of E1077 are similar to those of cefpirome except against P. aeruginosa and P. vulgaris.
Recently, many cephalosporins with broad antibacterial spectra, such as cefotaxime, cefuzonam, ceftazidime, cefpirome, and cefepime, have been developed and used in the therapy of bacterial infections (1, 2, 4, (6) (7) (8) .
E1077, 7,B-[2-(5-amino-1,2,4,-thiadiazole-3-yl)-(Z)-2-(fluoromethoxyiminoacetamido)] -3 -[(E) -3 -(carbamoylmethyl) ethylmethylammonio-1-propenyl]-3-cephem-4-carboxylate, is a novel parenteral cephalosporin with a broad antibacterial spectrum and activity against gram-positive and gram-negative bacteria including Staphylococcus aureus and Pseudomonas aeruginosa. In the study described here, we evaluated the in vitro and in vivo activities of E1077 and compared them with those of cefpirome, cefuzonam, ceftazidime, and cefotaxime.
MATERIALS AND METHODS Antimicrobial agents. E1077 was synthesized at the Tsukuba Research Laboratories of Eisai Co., Ltd., Ibaraki, Japan. The other antimicrobial agents were provided by the indicated manufacturers, as follows: cefpirome and cefotaxime, Hoechst Japan Limited, Saitama, Japan; cefuzonam, Lederle Japan Ltd., Tokyo, Japan; and ceftazidime, Nippon Glaxo Co., Ltd., Tochigi, Japan. Immediately after infection, the urethral meatus was clamped for 4 h. Two doses (10 and 40 mg/kg) of E1077, cefpirome, or ceftazidime were subcutaneously administered to mice 4 h after infection. At 24 h after drug administration, the kidneys were removed aseptically under diethyl ether anesthesia and homogenized in 3 ml of saline, and viable bacterial cells were determined by conventional plating techniques, in duplicate. The homogenized kidney sample was mixed with melting agar for bacterial count determinations, with the lowest CFU per kidney being 1.
Significant differences were established at the P < 0.05 level by using a nonparametric analysis of variance (KruskalWallis test) and then the Bonferroni multiple comparison test.
Levels of drugs in plasma and tissues of mice. Groups of five male strain ICR mice (weight, 18 to 20 g) were injected subcutaneously with 25 mg of each antibiotic agent per kg. At 5, 15, 30, 60, and 120 min after administration, blood, lung, and kidney samples were obtained from anesthetized animals and stored at 4°C. Plasma was separated by centrifugation and diluted with 1/15 M phosphate buffer (pH 6.0), and the tissues were slightly washed with phosphate buffer and homogenized with the same buffer. The homogenates were centrifuged, and the supematants were subjected to bioassay.
Bioassay. The concentrations of drugs were measured by the disk plate diffusion method by using E. coli ATCC 27166 with nutrient agar (Difco) as the test medium for E1077, cefpirome, and cefuzonam and Proteus mirabilis ATCC 21100 with DTS agar (Difco) as the test medium for ceftazidime. The antibiotic concentrations in plasma were calculated from the standard curve of compounds diluted in normal mouse plasma. The concentrations of the antibiotics in tissue were calculated from the standard curve of the compound dissolved in phosphate buffer. The assay sensitivities were 0.2 jig/ml for E1077 and ceftazidime, 0.4 ,ug/ml for cefpirome, and 0.1 ,ug/ml for cefuzonam. The betweenday coefficient of variation was <10% for all drugs. pneumoniae (MIC90 of E1077, 0.125 pg/ml), E1077 was as active as the other reference drugs except ceftazidime, which was less active than the other drugs. Against S. pyogenes, E1077 was as active as the other cephalosporins tested (MIC90, <0.06 ,ug/ml) and was more active than ceftazidime. Against Enterococcus faecalis, neither E1077 nor the reference drugs were significantly active. E1077 was active against most members of the family Enterobacteriaceae tested, but it was less active against Serratia marcescens and Proteus vulgaris. The MICgos of E1077 for E. coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, P. mirabilis, Providencia rettgeri, and Morganella morganii were less than 1 ,ug/ml. For Citrobacter freundii, the MIC90 of E1077 was 2 ,g/ml; E1077 had the same activity as cefpirome and was 30 times more active than the other reference compounds tested. E1077 also showed good activity against H. influenzae, as did the reference compounds. Moreover, E1077 had antibacterial activity against P. aeruginosa and Acinetobacter calcoaceticus. For P. aeruginosa, the MIC90 of E1077 was 16 ,g/ml and its activity was two to four times greater than those of ceftazidime and cefpirome. E1077 was also active againstA. calcoaceticus (MIC., 2.0 ,ug/ml); it was two to eight times more active than the other cephalosporins tested. Against Pseudomonas cepacia and Xanthomonas maltophilia, neither E1077 nor the other compounds had activity.
RESULTS
The MBC90s of E1077 are given in Table 1 . The MBC90s of E1077 were generally equal to or within two tube dilutions of the MIC90s. The bactericidal activity of E1077 was similar to those of the reference drugs.
In vivo efficacy in mice. (i) Bacteremic infection. The protective effect of E1077 on septicemia induced by grampositive and gram-negative bacteria in mice reflected its in vitro antibacterial activity (Table 2 ). E1077 showed a substantial protective effect against experimental S. aureus Smith infection, with an ED50 of 0.31 mg/kg; this ED50 was the same as that of cefpirome. E1077 was approximately 5 and 20 times more active than cefuzonam and ceftazidime, respectively. E1077 also demonstrated activity against S. aureus 90 infection; it was five times more effective than the reference drugs. Against E. coli, K pneumoniae, C. freundii, E. cloacae, and P. mirabilis, the ED5Os of E1077 were 0.123, 12.5, 0.39, 0.015, and 1.24 mg/kg, respectively; this activity was comparable to that of cefpirome. Against S.
marcescens, the ED50 of E1077 was 1.56 mg/kg, which was the same effect compared with the effects of the reference drugs. E1077 also possessed in vivo activities against P.
aeruginosa. Against P. aeruginosa E7, the ED50 of E1077 was 3.94 mg/kg, which was about two and six times more effective than ceftazidime and cefpirome, respectively. E1077 also had activity against P. aeruginosa 35 (ED50, 2.5 mg/kg); it was 10 times more active than cefpirome and was as active as ceftazidime. E1077 also demonstrated activity against A. calcoaceticus 240 infection which was comparable to that of cefpirome.
(ii) Pyelonephritic infection. The therapeutic effect of E1077 against pyelonephritic infections in mice caused by transurethral inoculation of mice with P. aeruginosa KU-1 was compared with those of cefpirome and ceftazidime (Table  3) . The bilateral kidneys of P. aeruginosa-infected untreated mice contained approximately 5.6 + 0.6 log CFU. Treatment Drug levels in plasma and tissues of mice. After subcutaneous administration of 25 mg of E1077 and related compounds per kg, the levels in plasma, kidneys, and lungs were measured (Fig. 1) . The 0. kidney ACKNOWLEDGMENT This study was supported by a grant from Eisai Co., Ltd., Tokyo, plasma T Japan.
